Novo Nordisk A/S $NVO Shares Sold by Stiles Financial Services Inc

Stiles Financial Services Inc trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 25.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,678 shares of the company’s stock after selling 10,587 shares during the quarter. Stiles Financial Services Inc’s holdings in Novo Nordisk A/S were worth $1,758,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. True Wealth Design LLC lifted its position in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares in the last quarter. NewSquare Capital LLC increased its stake in shares of Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth $37,000. Maseco LLP purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter worth $39,000. Finally, Copeland Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 47.3% during the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after acquiring an additional 186 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent analyst reports. Morgan Stanley reiterated an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. The Goldman Sachs Group lowered their target price on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, November 28th. CICC Research assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target for the company. Hsbc Global Res lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $56.21.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $60.70 on Wednesday. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The company has a fifty day simple moving average of $51.41 and a two-hundred day simple moving average of $54.76. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $271.00 billion, a price-to-earnings ratio of 17.64 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The firm had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.